GraniteShares 2x Long COIN Daily ETF vs Viatris Inc — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $5.05 (market cap $510.01M), while Viatris Inc trades at $17.49 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 39.3× GraniteShares 2x Long COIN Daily ETF's market cap, and Viatris Inc pays a 2.75% dividend while GraniteShares 2x Long COIN Daily ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long COIN Daily ETF for 15 Days and Viatris Inc for 57 Days on average.
| CONL | VTRS | |
|---|---|---|
Market Cap | $510.01M | $20.03B |
Volume | 21,041,836 | 14,109,977 |
Sector | Leveraged / Inverse | Health |
52-Week High | $48.58 | $18.27 |
52-Week Low | $3.93 | $9.74 |
Typical Hold Time | 15 Days | 57 Days |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Signals from Pluang's Aura AI — not financial advice
CONL shares declined 7.76% to $5.23, reflecting significant bearish technical momentum with moving averages signaling strong selling pressure. The ETF faces headwinds from underlying asset volatility, with recent news highlighting substantial losses in the leveraged product structure. Technical indicators show oversold conditions with RSI at 24.76, suggesting potential for near-term bounce despite the dominant downtrend.
The outlook remains challenging given the leveraged ETF's inherent volatility and recent performance struggles. While oversold technicals may provide short-term relief, the product's structure exposes investors to amplified losses during market declines. Risk management is critical given the 2x leverage and concentrated exposure to cryptocurrency-related equities.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.
The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →